A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
Public ClinicalTrials.gov record NCT03280550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to standard-of-care treatments. Study GA39855 (POLYP 2; NCT03280537) was another Phase III study by the Sponsor with identical objectives and design and was run in parallel with this study.
Study identification
- NCT ID
- NCT03280550
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2017
- Primary completion
- Mar 10, 2019
- Completion
- Mar 10, 2019
- Last update posted
- Mar 22, 2020
2017 – 2019
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jonathan Corren MD, Inc. | Los Angeles | California | 90025 | — |
| Sacramento Ear, Nose and Throat Surgical and Medical Group, Inc. - SacENT | Roseville | California | 95678 | — |
| Vitae Research Center | Miami | Florida | 33135 | — |
| Asthma & Allergy of Idaho | Twin Falls | Idaho | 83301 | — |
| Tandem Clinical Research, LLC | Marrero | Louisiana | 70072 | — |
| Montana Medical Research LLC | Missoula | Montana | 59808 | — |
| Northwell Health | Great Neck | New York | 11021 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Vital Prospects Clinical Research Institute PC - CRN | Tulsa | Oklahoma | 74136 | — |
| Medical University of South Carolina Hospital | Charleston | South Carolina | 29425 | — |
| Chrysalis Clinical Research | St. George | Utah | 84790 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03280550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2020 · Synced Sep 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03280550 live on ClinicalTrials.gov.